好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | H69 - Moving Your Lab: When, Why, and How (Research Hub)

Sunday 04/14/24
02:30 PM - 03:00 PM MDT Add To Calendar
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Hubs (Research)
Peter B. Kang, MD, FAAN
General Neurology, 好色先生, Research, and Methodology
Are you moving your laboratory in the future? Bring your questions and join the discussion on career timing, family timing, transferring grants, IRB and human subject issues, IACUC and animal issues, transferring big data, unexpected expenses that may eat into your start-up package, what equipment you can take with you, parting on good terms with your old institution, and what to expect at your new institution for the first year after a move.
No CME available
Professionalism
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist
Audience Participation

Program Evaluations

Event Timeline
02:30 PM - 03:00 PM MDT Speaker Moving Your Lab: When, Why, and How
Peter B. Kang, MD, FAAN
Faculty Disclosures
Peter B. Kang, MD, FAAN Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF Therapeutics (Italfarmaco). Dr. Kang has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. Dr. Kang has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. The institution of Dr. Kang has received research support from Xtraordinary Joy Foundation. The institution of an immediate family member of Dr. Kang has received research support from Sarepta Therapeutics. The institution of Dr. Kang has received research support from Centers for Disease Control and Prevention (CDC). The institution of Dr. Kang has received research support from National Institutes of Health (NIH). The institution of Dr. Kang has received research support from Food and Drug Administration. The institution of Dr. Kang has received research support from National Initiative for Cockayne Syndrome. The institution of Dr. Kang has received research support from Greg Marzolf Jr Foundation. The institution of Dr. Kang has received research support from Sarepta Therapeutics. The institution of Dr. Kang has received research support from Duchenne UK - PPMD. An immediate family member of Dr. Kang has received intellectual property interests from a discovery or technology relating to health care. Dr. Kang has received publishing royalties from a publication relating to health care. Dr. Kang has a non-compensated relationship as a Medical Advisory Board with Speak Foundation that is relevant to AAN interests or activities. Dr. Kang has a non-compensated relationship as a TRIAD Council with Hereditary Neuropathy Foundation that is relevant to AAN interests or activities. Dr. Kang has a non-compensated relationship as a President (Including President-Elect and Past President) with Child Neurology Society that is relevant to AAN interests or activities. Dr. Kang has a non-compensated relationship as a Board Member with Child Neurology Foundation that is relevant to AAN interests or activities.